Claudin-5: A Pharmacological Target to Modify the Permeability of the Blood-Brain Barrier.
blood–brain barrier
claudin-5
drug delivery system
tight junction
vascular stabilization
Journal
Biological & pharmaceutical bulletin
ISSN: 1347-5215
Titre abrégé: Biol Pharm Bull
Pays: Japan
ID NLM: 9311984
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
4
10
2021
pubmed:
5
10
2021
medline:
29
1
2022
Statut:
ppublish
Résumé
Claudin-5 is the dominant tight junction protein in brain endothelial cells and exclusively limits the paracellular permeability of molecules larger than 400 Da across the blood-brain barrier (BBB). Its pathological impairment or sustained down-regulation has been shown to lead to the progression of psychiatric and neurological disorders, whereas its expression under physiological conditions prevents the passage of drugs across the BBB. While claudin-5 enhancers could potentially act as vascular stabilizers to treat neurological diseases, claudin-5 inhibitors could function as delivery systems to enhance the brain uptake of hydrophilic small-molecular-weight drugs. Therefore, the effects of claudin-5 manipulation on modulating the BBB in different neurological diseases requires further examination. To manipulate claudin-5 expression levels and function, several claudin-5 modulating molecules have been developed. In this review, we first describe the molecular, cellular and pathological aspects of claudin-5 to highlight the mechanisms of claudin-5 enhancers/inhibitors. We then discuss recently developed claudin-5 enhancers/inhibitors and new methods to discover these molecules.
Identifiants
pubmed: 34602546
doi: 10.1248/bpb.b21-00408
doi:
Substances chimiques
Claudin-5
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM